AstraZeneca Plc AZN released on Wednesday topline data from RESOLUTE Phase 3 trial of Fasenra (benralizumab).AZN is showing upward bias. Get the complete picture here.Fasenra, despite showing numerical improvement, did not achieve statistical significance in the primary endpoint in patients with chronic obstructive pulmonary disease (COPD), also known as smoker’s lung disease.The safety and tolerability profile for Fasenra in the trial was consistent with the known profile of the medicine.The company will a ...